Topical therapies in inflammatory bowel disease

Digestion

Volumn 86, Issue SUPPL. 1, 2012, Pages 36-44

  Frei, Pascal ^a   Biedermann, Luc ^a   Manser, Christine N ^a   Wilk, Maike ^a   Manz, Michael ^c   Vavricka, Stephan R ^a,b   Rogler, Gerhard ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Division of Gastroenterology and Hepatology   (Switzerland)

^c Gastroenterology and Hepatology   (Switzerland)

Author keywords

Aminosalicylates; Enema; Foam; Topical therapy; Ulcerative colitis

Indexed keywords

ACETYLSALICYLIC ACID PLUS BUTALBITAL PLUS CAFFEINE; ALICAFORSEN; ARSENIC; ASALEX; ASAMAX; ASAVIXIN; ASAZINE; BECLOENEMA; BECLOMETHASON; BETAMETHASONE SODIUM PHOSPHATE; BUDENOFALK; BUDESONIDE; BUDO SAN; BUTYRIC ACID; COLITAN; CROHNAX; CYCLOSPORIN; ENEMA; ENTERAPROCT; ENTOCORD; HYDROCORTISONE; HYDROCORTISONE ACETATE; LABOXANTRYL; LOPERAMIDE; MESALAZINE; NEOPROCT; NICOTINE; PENTACOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; PRED KLYSMA; PREDENEMA; PREDNISOLONE; PREDNISOLONE 3 SULFOBENZOATE; PREDNISOLONE SODIUM PHOSPHATE; PROBIOTIC AGENT; PROCTOSTEROID; QUADRASA; QUOTA; SALAZOSULFAPYRIDINE; SCHERIPROCT; TACROLIMUS; TETRAHYDROLIPSTATIN; TIXOCORTOL PIVALATE; ULTRAPROCT; UNCLASSIFIED DRUG;

ACUTE PANCREATITIS; ALLERGIC REACTION; ANUS SPHINCTER; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CROHN DISEASE; CUSHINGOID SYNDROME; DISEASE ACTIVITY; DISEASE SEVERITY; DOSE RESPONSE; DRUG BIOAVAILABILITY; EVIDENCE BASED PRACTICE; HEADACHE; HUMAN; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; KIDNEY FAILURE; LOOSE FECES; MAINTENANCE THERAPY; MYOCARDITIS; OPEN STUDY; PANCREATITIS; PRIORITY JOURNAL; PROCTITIS; RELAPSE; REMISSION; SUPPOSITORY; TREMOR; ULCERATIVE COLITIS;

ADMINISTRATION, RECTAL; ANTI-INFLAMMATORY AGENTS; BUDESONIDE; COLITIS, ULCERATIVE; DRUG THERAPY, COMBINATION; ENEMA; GUIDELINE ADHERENCE; HUMANS; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; MESALAMINE; PATIENT COMPLIANCE; PRACTICE GUIDELINES AS TOPIC; SUPPOSITORIES;

EID: 84867542665     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000341947     Document Type: Article

References (63)

1. Bresci G, Parisi G, Gambardella L, Banti S, Bertoni M, Rindi G, Capria A: Evaluation of clinical patterns in ulcerative colitis: a long-term follow-up. Int J Clin Pharmacol Res 1997; 17:17-22.
2. Lakatos PL, Lakatos L: Ulcerative proctitis: a review of pharmacotherapy and management. Expert Opin Pharmacot her 2008; 9: 741-749.
3. Rogler G: Medical management of ulcerative colitis. Dig Dis 2009; 27:542-549.
4. Brunner M, Vogelsang H, Greinwald R, Kletter K, Kvaternik H, Schrolnberger C, Eichler HG, Brunner H, Dudczak R, Muller M: Colonic spread and serum pharmacoki-netics of budesonide foam in patients with mildly to moderately active ulcerative colitis. Aliment Pharmacol Ther 2005; 22:463-470.
5. Casellas F, Vaquero E, Armengol JR, Malage-lada JR: Practicality of 5-aminosalicylic suppositories for long-term treatment of inactive distal ulcerative colitis. Hepatogastroen-terology 1999; 46: 2343-2346.
6. Campieri M, Corbelli C, Gionchetti P, Brignola C, Belluzzi A, DiFebo G, Zagni P, Brunetti G, Miglioli M, Barbara L: Spread and distribution of 5-ASA colonic foam and 5-ASA enema in patients with ulcerative colitis. Dig Dis Sci 1992; 37: 1890-1897.
7. Travis SP, Stange EF, Lemann M, Oresland T, Bemelman WA, Chowers Y, Colombel JF, D'Haens G, Ghosh S, Marteau P, Kruis W, Mortensen NJ, Penninckx F, Gassull M: European evidence-based consensus on the management of ulcerative colitis: current management. J Crohn Colitis 2008; 2: 24-62.
8. Eliakim R, Tulassay Z, Kupcinskas L, Adamonis K, Pokrotnieks J, Bar-Meir S, Lavy A, Mueller R, Greinwald R, Chermesh I, Gross V: Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume me-salazine foam in active distal ulcerative colitis. Aliment Pharmacol Ther 2007; 26: 1237-1249.
9. Harris MS, Lichtenstein GR: Review article: delivery and efficacy of topical 5-aminosali-cylic acid (mesalazine) therapy in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2011; 33:996-1009.
10. D'Arienzo A, Panarese A, D'Armiento FP, Lancia C, Quattrone P, Giannattasio F, Boscaino A, Mazzacca G: 5-Aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosig-moiditis: a double-blind placebo-controlled clinical trial. Am J Gastroenterol 1990; 85: 1079-1082.
11. Gionchetti P, Rizzello F, Venturi A, Brignola C, Ferretti M, Peruzzo S, Campieri M: Comparison of mesalazine suppositories in proc-titis and distal proctosigmoiditis. Aliment Pharmacol Ther 1997; 11:1053-1057.
12. Marshall JK, Thabane M, Steinhart AH, Newman JR, Anand A, Irvine EJ: Rectal 5-aminosalicylic acid for induction of remission in ulcerative colit is. Cochrane Database Syst Rev 2010:CD004115.
13. Marshall JK, Irvine EJ: Rectal aminosalicy-late therapy for distal ulcerative colitis: a me-ta-analysis. A liment Pharmacol Ther 1995; 9: 293-300.
14. Marshall JK, Irvine EJ: Rectal corticoste-roids versus alternative treatments in ulcer-ative colitis: a meta-analysis. Gut 1997; 40: 775-781.
15. Mulder CJ, Fockens P, Meijer JW, van der Heide H, Wiltink EH, Tytgat GN: Beclo-methasone dipropionate (3 mg) versus 5-aminosalicyl ic acid (2 g) versus t he combination of both (3 mg/2 g) as retent ion enemas in active ulcerative proctitis. Eur J Gastroen-terol Hepatol 1996; 8: 549-553.
16. Safdi M, DeMicco M, Sninsky C, Banks P, Wruble L, Deren J, Koval G, Nichols T, Tar-gan S, Fleishman C, Wiita B: A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenter-ol 1997; 92:1867-1871.
17. Marteau P, Probert CS, Lindgren S, Gassul M, Tan TG, Dignass A, Befrits R, Midhagen G, Rademaker J, Foldager M: Combined oral and enema treatment with Pentasa (mesala-zine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 2005; 54: 960-965.
18. d'Albasio G, Trallori G, Ghetti A, Milla M, Nucci A, Pacini F, Morettini A: Intermittent therapy with high-dose 5-aminosalicylic acid enemas for maintaining remission in ul-cerative proctosigmoiditis. Dis Colon Rectum 1990; 33: 394-397.
19. Marteau P, Crand J, Foucault M, Rambaud JC: Use of mesalazine slow release suppositories 1 g three times per week to maintain remission of ulcerative proctitis: a randomised double blind placebo controlled multicentre study. Gut 1998; 42: 195-199.
20. Lichtenstein GR, Rutgeerts P: Importance of mucosal healing in ulcerative colitis. In-flamm Bowel Dis 2010; 16:338-346.
21. Romkens TE, Kampschreur MT, Drenth JP, van Oijen MG, de Jong DJ: High mucosal healing rates in 5-ASA-treated ulcerative colitis patients: results of a meta-analysis of clinical trials. Inflamm Bowel Dis 2012.
22. Sandborn WJ, Hanauer S, Lichtenstein GR, Safdi M, Edeline M, Scott Harris M: Early symptomatic response and mucosal healing w ith mesa la zi ne recta l su spension t herapy in active distal ulcerative colitis-additional results from two controlled studies. Aliment Pharmacol Ther 2011; 34: 747-756.
23. Tanswell IJ, Irfan K, Kossakowski T, Town-son G: Rectal perforation in ulcerative colitis: complication of an enema tip. Gastroin-test Endosc 2009; 69:344;disc 344.
24. Klotz U, Schwab M: Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease. Adv Drug Deliv Rev 2005; 57: 267-279.
25. Danielsson A, Lofberg R, Persson T, Salde L, Schioler R, Suhr O, Willen R: A steroid enema, budesonide, lacking systemic effects for the treatment of distal ulcerative colitis or proctitis. Scand J Gastroenterol 1992; 27: 9-12.
26. Hanauer SB, Robinson M, Pruitt R, Lazenby AJ, Persson T, Nilsson LG, Walton-Bowen K, Haskell LP, Levine JG: Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. US Budesonide enema study group. Gastroen-terolog y 1998; 115: 525-532.
27. Bili H, Algayres JP, Revel F, Coutant G, Daly JP: Acute adrenal insufficiency after stopping prolonged corticotherapy with betnesol enemas for ulcerative colitis (article in French). Gastroenterol Clin Biol 1998; 22: 1113-1114.
28. Gisbert JP, Gonzalez-Lama Y, Mate J: 5-Ami-nosalicylates and renal function in inflammatory bowel disease: a systematic review. Inf lamm Bowel Dis 2007; 13: 629-638.
29. Moss AC, Peppercorn MA: The risks and the benefits of mesalazine as a treatment for ul-cerative colitis. Expert Opin Drug Saf 2007; 6: 99-107.
30. Kim KH, Kim TN, Jang BI: A case of acute pancreatitis caused by 5-aminosalicylic acid suppositories in a patient with ulcerative colitis. Korean J Gastroenterol 2007; 50: 379-383.
31. Schworer H, Ramadori G: Acute pancreat it is-adverse effect of 5-aminosalicylic acid (me-salazine) in various galenic dosage forms. Dtsch Med Wochenschr 2000; 125: 1328-1330.
32. Kane SV, Cohen RD, Aikens JE, Hanauer SB: Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001; 96:2929-2933.
33. Sewitch MJ, Abrahamowicz M, Barkun A, Bitton A, Wild GE, Cohen A, Dobkin PL: Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol 2003; 98:1535-1544.
34. Kane SV, Huo D, Aikens J, Hanauer SB: Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003; 114:39-43.
35. Moody GA, Eaden JA, Helyes Z, Mayberry JF: Oral or rectal administration of drugs in IBD? A liment Pharmacol Ther 1997; 11: 999-1000.
36. Kane SV: Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006; 23: 577-585.
37. Kane SV, Brixner D, Rubin DT, Sewitch MJ: The challenge of compliance and persistence: focus on ulcerative colitis. J Manag Care Pharm 2008; 14:s2-s12;quiz s13-s15.
38. Fernandez-Becker NQ, Moss AC: Improving delivery of aminosalicylates in ulcerative colitis: effect on patient outcomes. Drugs 2008; 68:1089-1103.
39. Prantera C, Rizzi M: 5-ASA in ulcerative colitis: improving treatment compliance. World J Gastroenterol 2009; 15:4353-4355.
40. Cortot A, Maetz D, Degoutte E, Delette O, Meunier P, Tan G, Cazals JB, Dewit O, Hebuterne X, Beorchia S, Grunberg B, Leprince E, D'Haens G, Forestier S, Idier I, Lemann M: Mesalamine foam enema versus mesalamine liquid enema in active left-sided ulcerative colitis. Am J Gastroenterol 2008; 103:3106-3114.
41. Gross V, Bar-Meir S, Lavy A, Mickisch O, Tulassay Z, Pronai L, Kupcinskas L, Kiudelis G, Pokrotnieks J, Kovacs A, Faszczyk M, Razba-dauskas A, Margus B, Stolte M, Muller R, Greinwald R: Budesonide foam versus budesonide enema in active ulcerative proc-titis and proctosigmoiditis. Aliment Pharmacol Ther 2006; 23: 303-312.
42. Loening-Baucke V, Metcalf AM, Shirazi S: Anorectal manometry in active and quiescent ulcerative colitis. Am J Gastroenterol 1989; 84:892-897.
43. Rao SS, Read NW, Davison PA, Bannister JJ, Holdsworth CD: Anorectal sensitivity and responses to rectal distention in patients with ulcerative colitis. Gastroenterology 1987; 93: 1270-1275.
44. Suzuki H, Fujioka M: Rectal pressure and rectal compliance in ulcerative colitis. Jpn J Surg 1982; 12: 79-81.
45. Fox M, Stutz B, Menne D, Fried M, Schwizer W, Thumshirn M: The effects of loperamide on continence problems and anorectal function in obese subjects taking orlistat. Dig Dis Sci 2005; 50:1576-1583.
46. Gisbert JP, Gomollon F, Hinojosa J, Lopez San Roman A: Adherence of gastroenterolo-gists to European Crohn's and Colitis Organisation consensus on ulcerative colitis: a real-life survey in Spain. J Crohn Colitis 2010; 4: 567-574.
47. Reddy SI, Friedman S, Telford JJ, Strate L, Ookubo R, Banks PA: Are patients with inflammatory bowel disease receiving optimal care? Am J Gastroenterol 2005; 100:1357-1361.
48. Lawrance IC: Novel topical therapies for distal colitis. World J Gastrointest Pharmacol Ther 2010; 1:87-93.
49. Matthes H, Krummenerl T, Giensch M, Wolff C, Schulze J: Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN). BMC Complement Altern Med 2010; 10: 13.
50. Bennet JD, Brinkman M: Treatment of ulcer-ative colitis by implantation of normal co-lonic f lora. Lancet 1989; 1(8630).
51. Borody TJ, Campbell J: Fecal microbiota transplantation: current status and future directions. Expert Rev Gastroenterol Hepa-tol 2011; 5:653-655.
52. Vermeire S, Joossens M, Verbeke K, Hildeb-rand F, Machiels K, Van den Broeck K, Van Assche G, P.J. R, Raes J: Pilot study on the safety and efficacy of faecal microbiota transplantation in refractory Crohn's disease. Gastroenterology 2012; 1425:S-360.
53. Lawrance IC, Copeland TS: Rectal tacroli-mus in the treatment of resistant ulcerative proctitis. Aliment Pharmacol Ther 2008; 28: 1214-1220.
54. van Dieren JM, van Bodegraven AA, Kuipers EJ, Bakker EN, Poen AC, van Dekken H, Nieuwenhuis EE, van der Woude CJ: Local application of tacrolimus in distal colitis: feasible and safe. Inflamm Bowel Dis 2009; 15: 193-198.
55. Miner PB Jr, Geary RS, Matson J, Chuang E, Xia S, Baker BF, Wedel MK: Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis. A liment Pharmacol Ther 2006; 23: 1427-1434.
56. Miner P, Wedel M, Bane B, Bradley J: An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion mole-cule-1, in the treatment of chronic, unremitting pouchitis. Aliment Pharmacol Ther 2004; 19: 281-286.
57. Sandborn WJ, Tremaine WJ, Schroeder KW, Steiner BL, Batts K P, Lawson GM: Cyclospo-rine enemas for treatment-resistant, mildly to moderately active, left-sided ulcerative colitis. Am J Gastroenterol 1993; 88: 640-645.
58. Sandborn WJ, Tremaine WJ, Schroeder KW, Batts KP, Lawson GM, Steiner BL, Harrison JM, Zinsmeister AR: A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. Gastroenterology 1994; 106:1429-1435.
59. Scheppach W, Sommer H, Kirchner T, Pa-ganelli GM, Bartram P, Christl S, Richter F, Dusel G, Kasper H: Effect of but yrate enemas on the colonic mucosa in distal ulcerative colitis. Gastroenterology 1992; 103: 51-56.
60. Scheppach W: Treatment of distal ulcerative colitis with short-chain fatty acid enemas. A placebo-controlled trial. German-Austrian SCFA Study Group. Dig Dis Sci 1996; 41: 2254-2259.
61. Pedersen G, Brynskov J: Topical rosigli-tazone treatment improves ulcerative colitis by restoring peroxisome proliferator-acti-vated receptor-gamma activity. Am J Gastroenterol 2010; 105:1595-1603.
62. Ingram JR, Thomas GA, Rhodes J, Green JT, Hawkes ND, Swift JL, Srivastava ED, Evans BK, Williams GT, Newcombe RG, Courtney E, Pillai S: A randomized tria l of nicotine enemas for active ulcerative colitis. Clin Gastroenterol Hepatol 2005; 3:1107-1114.
63. Forbes A, Britton TC, House IM, Gazzard BG: Safety and efficacy of acetarsol suppositories in unresponsive proctitis. Aliment Pharmacol Ther 1989; 3: 553-556.